Related Experiment Video
Updated: Feb 11, 2026

Technique to Target Microinjection to the Developing Xenopus Kidney
Published on: May 3, 2016
Are Pax proteins potential therapeutic targets in kidney disease and cancer?
Edward Grimley1, Gregory R Dressler1
1Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract:
Pax genes encode developmental regulators that are expressed in a variety of tissues and control critical events in morphogenesis. In the kidney, Pax2 and Pax8 are expressed in embryonic development and in specific renal diseases associated with aberrant epithelial cell proliferation. Prior genetic and cell biological studies suggest that reducing the activity of Pax proteins in renal cancer or in polycystic kidney disease can slow the progression of these conditions. The Pax proteins may be critical for providing tissue and locus specificity to recruit epigenetic modifiers that control gene expression and chromatin structure. Although they are nuclear, targeting Pax proteins to inhibit function may be feasible with small molecules. Such inhibition of Pax protein function may provide novel therapies for subsets of renal disorders that are tissue- and cell type-specific and avoid systemic effects on non-Pax-expressing cells and tissues. Given the paucity of effective treatments for renal cancer and cystic disease, the Pax family of proteins represents new pharmaceutical targets that merit exploration and further development.
Insights
Pax proteins (Paired box) are key developmental regulators. Inhibiting Pax proteins in kidney diseases like cancer or polycystic kidney disease may offer targeted therapies with fewer side effects.
Area of Science:
- Developmental Biology
- Molecular Biology
- Nephrology
Background:
- Pax genes encode crucial developmental regulators involved in morphogenesis.
- Pax2 and Pax8 are expressed in kidney development and diseases characterized by abnormal epithelial cell proliferation.
- Previous research suggests that reducing Pax protein activity can impede the progression of renal cancer and polycystic kidney disease.
Purpose of the Study:
- To explore the therapeutic potential of targeting Pax proteins in renal disorders.
- To investigate Pax proteins as pharmaceutical targets for specific kidney diseases.
Main Methods:
- Review of prior genetic and cell biological studies on Pax proteins in renal development and disease.
- Analysis of the role of Pax proteins in recruiting epigenetic modifiers.
- Consideration of small molecule inhibitors for targeting nuclear Pax proteins.
Main Results:
- Pax proteins are critical for tissue and locus specificity in gene regulation and chromatin structure.
- Targeting Pax proteins could offer tissue- and cell type-specific therapies for renal disorders.
- Inhibition of Pax proteins may slow the progression of conditions like renal cancer and polycystic kidney disease.
Conclusions:
- Pax proteins represent promising pharmaceutical targets for treating specific renal disorders.
- Targeted inhibition of Pax proteins may provide novel therapeutic strategies with reduced systemic effects.
- Further exploration and development of Pax protein inhibitors are warranted for renal cancer and cystic kidney disease.
More Related Videos
06:19Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Related Concept Videos
Chronic Kidney Disease I: Introduction
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chronic Kidney Disease II: Clinical Manifestations
Kidney Structure
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management